Raymond James & Associates Fate Therapeutics Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$9.86 - $23.83 $22,076 - $53,355	-2,239 Reduced 8.3%	24,745 $249,000
Q3 2022 Oct 25, 2022	SELL	$21.04 - $36.06 $59,564 - $102,085	-2,831 Reduced 9.5%	26,984 $605,000
Q2 2022 Aug 12, 2022	BUY	$17.78 - $42.39 $6,738 - $16,065	379 Added 1.29%	29,815 $739,000
Q1 2022 May 11, 2022	BUY	$29.67 - $60.28 $260,799 - $529,861	8,790 Added 42.57%	29,436 $1.14 Million
Q4 2021 Feb 08, 2022	BUY	$47.84 - $64.34 $11,960 - $16,085	250 Added 1.23%	20,646 $1.21 Million
Q3 2021 Nov 02, 2021	BUY	$59.27 - $95.73 $21,040 - $33,984	355 Added 1.77%	20,396 $1.21 Million
Q2 2021 Aug 11, 2021	BUY	$67.25 - $92.52 $1,076 - $1,480	16 Added 0.08%	20,041 $1.74 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $211,717 - $344,451	-2,934 Reduced 12.78%	20,025 $1.65 Million
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $96,520 - $255,807	2,534 Added 12.41%	22,959 $2.09 Million
Q3 2020 Nov 04, 2020	SELL	$30.41 - $40.5 $28,129 - $37,462	-925 Reduced 4.33%	20,425 $816,000
Q2 2020 Jul 28, 2020	SELL	$20.21 - $35.23 $18,189 - $31,706	-900 Reduced 4.04%	21,350 $733,000
Q1 2020 Apr 21, 2020	SELL	$17.28 - $31.88 $207,308 - $382,464	-11,997 Reduced 35.03%	22,250 $494,000
Q4 2019 Feb 12, 2020	SELL	$13.39 - $20.73 $83,151 - $128,733	-6,210 Reduced 15.35%	34,247 $670,000
Q3 2019 Nov 07, 2019	BUY	$15.47 - $22.5 $90,019 - $130,927	5,819 Added 16.8%	40,457 $628,000
Q2 2019 Aug 06, 2019	BUY	$15.61 - $20.44 $32,624 - $42,719	2,090 Added 6.42%	34,638 $703,000
Q1 2019 May 06, 2019	BUY	$13.15 - $18.71 $67,196 - $95,608	5,110 Added 18.62%	32,548 $572,000
Q4 2018 Feb 11, 2019	SELL	$11.48 - $16.98 $21,238 - $31,413	-1,850 Reduced 6.32%	27,438 $352,000
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $18,243 - $33,964	2,085 Added 7.66%	29,288 $477,000
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $4,149 - $6,106	453 Added 1.69%	27,203 $308,000
Q1 2018 May 14, 2018	BUY	$6.3 - $13.77 $23,467 - $51,293	3,725 Added 16.18%	26,750 $261,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $90,718 - $152,886	23,025	23,025 $141,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account